Acute effects of sublingual buprenorphine on brain responses to heroin-related cues in early-abstinent heroin addicts: An uncontrolled trial

Neuroscience

Volumn 170, Issue 3, 2010, Pages 808-815

  Mei, W ^a,b   Zhang, J X ^c   Xiao, Z ^a,b,d  

^a THE FIRST AFFILIATED HOSPITAL OF SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^b SHANTOU UNIVERSITY MEDICAL COLLEGE   (China)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d Shantou Second People's Hospital   (China)

Author keywords

Addiction; Buprenorphine; FMRI; Heroin; Relapse; Replacement therapy

Indexed keywords

BUPRENORPHINE;

ADULT; AMYGDALOID NUCLEUS; ARTICLE; ASSOCIATION; BRAIN REGION; CINGULATE GYRUS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG RESPONSE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; HEROIN DEPENDENCE; HIPPOCAMPUS; HUMAN; IMAGE ANALYSIS; NEUROBIOLOGY; ORBITAL CORTEX; PARIETAL LOBE; PREFRONTAL CORTEX; PRIORITY JOURNAL; QUESTIONNAIRE; RELAPSE; SELF REPORT; THALAMUS; VENTRAL TEGMENTUM; VISUAL STIMULATION; WITHDRAWAL SYNDROME;

EID: 79957440489     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuroscience.2010.07.033     Document Type: Article

References (41)

1. Bertolino A., Blasi G., Caforio G., Latorre V., De Candia M., Rubino V., Callicott J.H., Mattay V.S., Bellomo A., Scarabino T., Weinberger D.R., Nardini M. Functional lateralization of the sensorimotor cortex in patients with schizophrenia: effects of treatment with olanzapine. Biol Psychiatry 2004, 56:190-197.
2. Chawarski M.C., Moody D.E., Pakes J., O'Connor P.G., Schottenfeld R.S. Buprenorphine tablet versus liquid: a clinical trial comparing plasma levels, efficacy, and symptoms. J Subst Abus Treat 2005, 29:307-312.
3. Ciraulo D.A., Hitzemann R.J., Somoza E., Knapp C.M., Rotrosen J., Sarid-Segal O., Ciraulo A.M., Greenblatt D.J., Chiang C.N. Pharmacokinetics and pharmacodynamics of multiple sublingual buprenorphine tablets in dose-escalation trials. J Clin Pharmacol 2006, 46:179-192.
4. Collins G.B., McAllister M.S. Buprenorphine maintenance: a new treatment for opioid dependence. Cleve Clin J Med 2007, 74:514-520.
5. Conrad K.L., Tseng K.Y., Uejima J.L., Reimers J.M., Heng L.J., Shaham Y., Marinelli M., Wolf M.E. Formation of accumbens GluR2-lacking AMPA receptors mediates incubation of cocaine craving. Nature 2008, 454:118-121.
6. Dackis C., O'Brien C. Neurobiology of addiction: treatment and public policy ramifications. Nat Neurosci 2005, 8:1431-1436.
7. Daglish M.R., Nutt D.J. Brain imaging studies in human addicts. Eur Neuropsychopharmacol 2003, 13:453-458.
8. Everitt B.J., Robbins T.W. Neural systems of reinforcement for drug addiction: from actions to habits to compulsion. Nat Neurosci 2005, 8:1481-1489.
9. Garavan H., Pankiewicz J., Bloom A., Cho J.K., Sperry L., Ross T.J., Salmeron B.J., Risinger R., Kelley D., Stein E.A. Cue-induced cocaine craving: neuroanatomical specificity for drug users and drug stimuli. Am J Psychiatry 2000, 157:1789-1798.
10. Grill-Spector K., Henson R., Martin A. Repetition and the brain: neural models of stimulus-specific effects. Trends Cogn Sci 2006, 10:14-23.
11. Gutstein H.B., Akil H. Opioid analgesics. Goodman & Gilman's the pharmacological basis of therapeutics 2006, McGraw-Hill, New York, NY. L. Brunton, J. Lazo (Eds.).
12. Heidbreder C.A., Hagan J.J. Novel pharmacotherapeutic approaches for the treatment of drug addiction and craving. Curr Opin Pharmacol 2005, 5:107-118.
13. Honey G., Bullmore E. Human pharmacological MRI. Trends Pharmacol Sci 2004, 25:366-374.
14. Hutcheson D.M., Everitt B.J., Robbins T.W., Dickinson A. The role of withdrawal in heroin addiction: enhances reward or promotes avoidance?. Nat Neurosci 2001, 4:943-947.
15. Kreek M.J., LaForge K.S., Butelman E. Pharmacotherapy of addictions. Nat Rev Drug Discov 2002, 1:710-726.
16. Langleben D.D., Ruparel K., Elman I., Busch-Winokur S., Pratiwadi R., Loughead J., O'Brien C.P., Childress A.R. Acute effect of methadone maintenance dose on brain FMRI response to heroin-related cues. Am J Psychiatry 2008, 165:390-394.
17. Lawrence N.S., Ross T.J., Stein E.A. Cognitive mechanisms of nicotine on visual attention. Neuron 2002, 36:539-548.
18. Lee T.M., Zhou W.H., Luo X.J., Yuen K.S., Ruan X.Z., Weng X.C. Neural activity associated with cognitive regulation in heroin users: a fMRI study. Neurosci Lett 2005, 382:211-216.
19. Leonardi C., Hanna N., Laurenzi P., Fagetti R. Multi-centre observational study of buprenorphine use in 32 Italian drug addiction centres. Drug Alcohol Depend 2008, 94:125-132.
20. Leslie R.A., James M.F. Pharmacological magnetic resonance imaging: a new application for functional MRI. Trends Pharmacol Sci 2000, 21:314-318.
21. Ling W., Wesson D.R. Clinical efficacy of buprenorphine: comparisons to methadone and placebo. Drug Alcohol Depend 2003, 70:S49-S57.
22. Lingford-Hughes A. Human brain imaging and substance abuse. Curr Opin Pharmacol 2005, 5:42-46.
23. Mendelson J., Jones R.T., Welm S., Baggott M., Fernandez I., Melby A.K., Nath R.P. Buprenorphine and naloxone combinations: the effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psychopharmacology (Berl) 1999, 141:37-46.
24. Nestler E.J. Reinforcement and addictive disorders. Molecular neuropharmacology: a foundation for clinical neuroscience 2009, McGraw-Hill, New York, NY. E.J. Nestler (Ed.).
25. O'Brien C.P. Anticraving medications for relapse prevention: a possible new class of psychoactive medications. Am J Psychiatry 2005, 162:1423-1431.
26. Oreskovich M.R., Saxon A.J., Ellis M.L., Malte C.A., Reoux J.P., Knox P.C. A double-blind, double-dummy, randomized, prospective pilot study of the partial mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend 2005, 77:71-79.
27. Sell L.A., Morris J., Bearn J., Frackowiak R.S., Friston K.J., Dolan R.J. Activation of reward circuitry in human opiate addicts. Eur J Neurosci 1999, 11:1042-1048.
28. Srivastava A., Kahan M. Buprenorphine: a potential new treatment option for opioid dependence. CMAJ 2006, 174:1835.
29. Strain E.C., Moody D.E., Stoller K.B., Walsh S.L., Bigelow G.E. Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 2004, 74:37-43.
30. Tracey I. Prospects for human pharmacological functional magnetic resonance imaging (phMRI). J Clin Pharmacol Suppl 2001, 41:21S-28S.
31. Volkow N.D., Fowler J.S., Wang G.J. The addicted human brain: insights from imaging studies. J Clin Invest 2003, 111:1444-1451.
32. Volkow N.D., Fowler J.S., Wang G.J., Baler R., Telang F. Imaging dopamine's role in drug abuse and addiction. Neuropharmacology 2009, 56(Suppl 1):3-8.
33. Volkow N.D., Fowler J.S., Wang G.J., Swanson J.M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004, 9:557-569.
34. Volkow N.D., Wang G.J., Ma Y., Fowler J.S., Wong C., Jayne M., Telang F., Swanson J.M. Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage 2006, 32:1782-1792.
35. Volkow N.D., Wang G.J., Ma Y., Fowler J.S., Zhu W., Maynard L., Telang F., Vaska P., Ding Y.S., Wong C., Swanson J.M. Expectation enhances the regional brain metabolic and the reinforcing effects of stimulants in cocaine abusers. J Neurosci 2003, 23:11461-11468.
36. Volkow N.D., Wang G.J., Telang F., Fowler J.S., Logan J., Childress A.R., Jayne M., Ma Y., Wong C. Cocaine cues and dopamine in dorsal striatum: mechanism of craving in cocaine addiction. J Neurosci 2006, 26:6583-6588.
37. Weiss F. Neurobiology of craving, conditioned reward and relapse. Curr Opin Pharmacol 2005, 5:9-19.
38. Wilson S.J., Sayette M.A., Fiez J.A. Prefrontal responses to drug cues: a neurocognitive analysis. Nat Neurosci 2004, 7:211-214.
39. Woody G.E., Poole S.A., Subramaniam G., Dugosh K., Bogenschutz M., Abbott P., Patkar A., Publicker M., McCain K., Potter J.S., Forman R., Vetter V., McNicholas L., Blaine J., Lynch K.G., Fudala P. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA 2008, 300:2003-2011.
40. Xiao Z., Lee T., Zhang J.X., Wu Q., Wu R., Weng X., Hu X. Thirsty heroin addicts show different fMRI activations when exposed to water-related and drug-related cues. Drug Alcohol Depend 2006, 83:157-162.
41. Zijlstra F., Veltman D.J., Booij J., van den Brink W., Franken I.H. Neurobiological substrates of cue-elicited craving and anhedonia in recently abstinent opioid-dependent males. Drug Alcohol Depend 2009, 99:183-192.